To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
VC-backed Graphite Bio raises $238m for IPO
Graphite Bio, a gene editing company focused on treating or curing serious diseases, has raised $238 million for its IPO after pricing its 14 million shares at $17 per share.
